US › Healthcare

Ocugen Inc (OCGN)

US · Healthcare · Biotechnology

$1.31+4.80%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$1.5M
Revenue YoY
+3.5%
Net profit
$-19.2M
Profit YoY
-24.9%
EPS
$-0.06
EPS estimate
$-0.05
Net margin
-1,250.9%

EPS came in at -0.06 against a street estimate of -0.05 — a miss of 20.0%.

Key statistics

Market cap
$416.4M
Forward P/E
13.1
P/B
72.89
Book value
$0.02
EPS (TTM)
$-0.24
52-week high
$2.73
52-week low
$0.93
50-day MA
$1.35
200-day MA
$1.53
Beta
2.18

Analyst view

Analysts rate Ocugen Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $12.17.

Shareholding

Insiders
1.68%
Institutions
34.30%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC4.08%
Millennium Management LLC4.05%
State Street Corp2.86%
Marshall Wace Asset Management Ltd2.38%
BlackRock Inc2.16%
UBS Group AG2.15%
RTW INVESTMENTS, LLC1.97%
Geode Capital Management, LLC1.25%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Ocugen Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.